These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 23242450)

  • 1. Adjuvant therapy for resected non-small-cell lung cancer with lymphovascular invasion.
    Rami-Porta R
    J Thorac Oncol; 2013 Jan; 8(1):e9-10. PubMed ID: 23242450
    [No Abstract]   [Full Text] [Related]  

  • 2. Lymphovascular invasion in non-small-cell lung cancer.
    Salvati F
    J Thorac Oncol; 2013 Jan; 8(1):e8-9. PubMed ID: 23242449
    [No Abstract]   [Full Text] [Related]  

  • 3. Lymphovascular invasion in non-small-cell lung cancer: implications for staging and adjuvant therapy.
    Higgins KA; Chino JP; Ready N; D'Amico TA; Berry MF; Sporn T; Boyd J; Kelsey CR
    J Thorac Oncol; 2012 Jul; 7(7):1141-7. PubMed ID: 22617241
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lymph node ratio may predict the benefit of postoperative radiotherapy in non-small-cell lung cancer.
    Urban D; Bar J; Solomon B; Ball D
    J Thorac Oncol; 2013 Jul; 8(7):940-6. PubMed ID: 23695418
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Overexpression of the mammalian target of rapamycin: a novel biomarker for poor survival in resected early stage non-small cell lung cancer.
    Dhillon T; Mauri FA; Bellezza G; Cagini L; Barbareschi M; North BV; Seckl MJ
    J Thorac Oncol; 2010 Mar; 5(3):314-9. PubMed ID: 20093977
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sarcoidal reactions in regional lymph nodes of patients with early stage non-small cell lung cancer predict improved disease-free survival: a pilot case-control study.
    Steinfort DP; Tsui A; Grieve J; Hibbs ML; Anderson GP; Irving LB
    Hum Pathol; 2012 Mar; 43(3):333-8. PubMed ID: 21835432
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Association of Intratumoral Germinal Centers with early-stage non-small cell lung cancer.
    Gottlin EB; Bentley RC; Campa MJ; Pisetsky DS; Herndon JE; Patz EF
    J Thorac Oncol; 2011 Oct; 6(10):1687-90. PubMed ID: 21642860
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Fatal massive pulmonary hemorrhage due to bronchial carcinoma].
    Haupt R
    Frankf Z Pathol; 1966; 75(5):412-8. PubMed ID: 16300334
    [No Abstract]   [Full Text] [Related]  

  • 9. Sorafenib in patients with advanced non-small cell lung cancer that harbor K-ras mutations: a brief report.
    Smit EF; Dingemans AM; Thunnissen FB; Hochstenbach MM; van Suylen RJ; Postmus PE
    J Thorac Oncol; 2010 May; 5(5):719-20. PubMed ID: 20421765
    [No Abstract]   [Full Text] [Related]  

  • 10. Mediastinal lymph node examination and survival in resected early-stage non-small-cell lung cancer in the surveillance, epidemiology, and end results database.
    Osarogiagbon RU; Yu X
    J Thorac Oncol; 2012 Dec; 7(12):1798-1806. PubMed ID: 23154551
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The prognostic value of ratio-based lymph node staging in resected non-small-cell lung cancer.
    Qiu C; Dong W; Su B; Liu Q; Du J
    J Thorac Oncol; 2013 Apr; 8(4):429-35. PubMed ID: 23486264
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Cytological fine diagnosis in pulmology].
    Fischnaller M
    Osterr Z Onkol; 1977 Dec; 4(4):65-80. PubMed ID: 202905
    [No Abstract]   [Full Text] [Related]  

  • 13. Features and prognostic factors of large node-negative non-small-cell lung cancers shifted to stage II.
    Toffalorio F; Radice D; Spaggiari L; Sinno V; Barberis M; Spitaleri G; Giovannini M; Delmonte A; Catania C; Noberasco C; Brambilla D; de Braud F; Veronesi G; Solli P; De Pas T
    J Thorac Oncol; 2012 Jul; 7(7):1124-30. PubMed ID: 22610258
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Analysis of the T descriptors and other prognosis factors in pathologic stage I non-small cell lung cancer in China.
    Li Z; Yu Y; Lu J; Luo Q; Wu C; Liao M; Zheng Y; Ai X; Gu L; Lu S
    J Thorac Oncol; 2009 Jun; 4(6):702-9. PubMed ID: 19404215
    [TBL] [Abstract][Full Text] [Related]  

  • 15. On lymph node trays in lung cancer surgery.
    Osarogiagbon RU
    J Thorac Oncol; 2013 Jan; 8(1):e8. PubMed ID: 23242448
    [No Abstract]   [Full Text] [Related]  

  • 16. On lymph node trays in lung cancer surgery.
    Molnar TF
    J Thorac Oncol; 2013 Jan; 8(1):e8. PubMed ID: 23242447
    [No Abstract]   [Full Text] [Related]  

  • 17. Erlotinib in advanced non-small cell lung cancer: efficacy and safety findings of the global phase IV Tarceva Lung Cancer Survival Treatment study.
    Reck M; van Zandwijk N; Gridelli C; Baliko Z; Rischin D; Allan S; Krzakowski M; Heigener D
    J Thorac Oncol; 2010 Oct; 5(10):1616-22. PubMed ID: 20736854
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Preferential histiotypic expression of CD44-isoforms in human lung cancer.
    Wimmel A; Schilli M; Kaiser U; Havemann K; Ramaswamy A; Branscheid D; Kogan E; Schuermann M
    Lung Cancer; 1997 Mar; 16(2-3):151-72. PubMed ID: 9152947
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Incidence of non-small-cell lung cancer among California Hispanics according to neighborhood socioeconomic status.
    Wong ML; Clarke CA; Yang J; Hwang J; Hiatt RA; Wang S
    J Thorac Oncol; 2013 Mar; 8(3):287-94. PubMed ID: 23399956
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Everolimus and erlotinib as second- or third-line therapy in patients with advanced non-small-cell lung cancer.
    Papadimitrakopoulou VA; Soria JC; Jappe A; Jehl V; Klimovsky J; Johnson BE
    J Thorac Oncol; 2012 Oct; 7(10):1594-601. PubMed ID: 22968184
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.